- Orciprenaline
-
Orciprenaline Systematic (IUPAC) name (RS)-5-[1-hydroxy-2-(isopropylamino)ethyl]benzene-1,3-diol Clinical data AHFS/Drugs.com monograph MedlinePlus a682084 Pregnancy cat. A(AU) C(US) Legal status ℞-only (US) Routes Inhalation / tablets Pharmacokinetic data Bioavailability 3% if inhaled, 40% if taken orally Metabolism Gastrointestinal and hepatic Half-life 6 hours Identifiers CAS number 586-06-1 ATC code R03AB03 R03CB03
R03CB53PubChem CID 4086 DrugBank DB00816 ChemSpider 3944 UNII 53QOG569E0 KEGG D08300 ChEMBL CHEMBL776 Chemical data Formula C11H17NO3 Mol. mass 211.258 g/mol SMILES eMolecules & PubChem Physical data Solubility in water 9.7 mg/mL (20 °C) (what is this?) (verify) Orciprenaline (INN, also known as metaproterenol) is a bronchodilator used in the treatment of asthma. Orciprenaline is a moderately selective beta2-adrenergic receptor agonist that stimulates receptors of the smooth muscle in the lungs, uterus, and vasculature supplying skeletal muscle, with minimal or no effect on alpha-adrenergic receptors. The pharmacologic effects of beta adrenergic agonist drugs, such as orciprenaline, are at least in part attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of ATP to cAMP. Increased cAMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from many cells, especially from mast cells.
This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.